<DOC>
	<DOC>NCT00554099</DOC>
	<brief_summary>The purpose of this study is to determine whether Asacol® 2.4 g/day (400 mg Mesalamine) is safe and effective in the treatment of diverticulitis.</brief_summary>
	<brief_title>Asacol Acute Diverticulitis(DIVA)Study</brief_title>
	<detailed_description>This study is designed to evaluate the safety and efficacy of Asacol® 2.4 g/day in generally healthy, adult patients who have had an attack of acute diverticulitis. The study will evaluate the safety and efficacy of a 12 week treatment with Asacol® followed a 9 month non-treatment observation period in approximately 180 patients with acute diverticulitis.</detailed_description>
	<mesh_term>Diverticulitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>A clinical diagnosis of acute diverticulitis Female patients must be postmenopausal (at least 1 year without spontaneous menses) or surgically sterile or have a negative urine pregnancy test and practice acceptable contraception (e.g., abstinence; oral, intramuscular, or implanted hormonal contraception [at least 3 months prior to enrollment]; 2barrier methods [e.g., condom, diaphragm, or spermicide]; intrauterine device or verbal report of partner with history of nonreversed vasectomy) Willing and able to participate in the study and provide a signed informed consent Presence of diverticular complications (e.g., fistula, abscess, obstruction, stenosis); Active or recent history (within 6 months) of a peptic ulcer; Prior history of irritable bowel syndrome (IBS), as determined by the Investigator; History of major abdominal surgery (as determined by the Investigator); History of GI surgery within 3 months of diagnosis of acute diverticulitis; History of immunocompromising disease, human immunodeficiency virus (HIV) infection, or acquired immunodeficiency syndrome (AIDS); If female patient, active or recent history of endometriosis or dysmenorrhea; Received a dose of a product that contains, or is metabolized to, mesalamine by any route within 4 weeks before the screening visit;</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>